Anavex Life Sciences Corp. (NASDAQ: AVXL) is named one of the 10 Best Debt Free Small Cap Stocks to Buy Now. H.C. Wainwright reiterates its ‘Buy’ rating on AVXL with a $42 price target after new Phase 2b/3 Alzheimer’s data.

AVXL shares are trading below the target, showing significant upside potential. The company’s oral therapy blarcamesine demonstrates reduced cognitive decline in early Alzheimer’s patients, boosting confidence in its precision medicine approach. AVXL focuses on developing therapeutics for neurodegenerative disorders.

While AVXL shows promise as an investment, some AI stocks offer higher upside potential with less downside risk. For an undervalued AI stock benefiting from Trump-era tariffs and the onshoring trend, check out the best short-term AI stock. Explore stocks benefiting from AI and the best quantum computing stocks according to Wall Street analysts.

Disclosure: None.

Read more at Yahoo Finance: H.C. Wainwright Reiterates Its ‘Buy’ Rating on Anavex Life Sciences Corp. (AVXL) with a $42 Price Target